CClinicalTrials.gg
Not yet recruitingNCT07845877Updated Sep 29, 2026

An Intervention to Reduce Sedentary Behavior and Promote Physical Activity in Colorectal Cancer Chemotherapy

An interventional study of Sedentary behavior reduction intervention for patients with colorectal cancer undergoing chemotherapy in Colorectal Neoplasms and Sedentary Behavior, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Yonsei University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

This single-group feasibility study develops and evaluates an intervention designed to reduce sedentary behavior and promote physical activity in patients with colorectal cancer undergoing chemotherapy. During chemotherapy, treatment-related symptoms such as fatigue often lead to reduced physical activity and prolonged sitting time. Replacing sedentary time with light-intensity movement is associated with improved metabolic outcomes and a lower risk of several chronic conditions, including cancer. The intervention is developed using the Capability, Opportunity, Motivation-Behavior (COM-B) model and the Behavior Change Wheel (BCW), and is delivered over 3 weeks using a smartwatch. It comprises smartwatch-based prompts to interrupt prolonged sitting, symptom assessment and symptom-management education, and feedback on physical activity and sedentary behavior. Sedentary behavior and physical activity are measured objectively by smartwatch continuously before, during, and after the 3-week intervention. The primary aim is to evaluate the feasibility of the intervention across the domains of acceptability, demand, implementation, and practicality. Secondary aims explore preliminary changes in physical activity, sedentary behavior, symptoms, health-related quality of life, and self-efficacy to reduce sedentary behavior. The findings are intended to inform the development of future interventions and nursing care to support health management in patients with cancer.

Read the detailed description

Background and rationale: Patients with colorectal cancer undergoing chemotherapy frequently experience symptoms such as fatigue that reduce physical activity and increase sedentary time. Prolonged sedentary behavior is independently associated with adverse health outcomes, whereas replacing sitting with light-intensity activity confers metabolic and other health benefits. Reducing sedentary behavior is a feasible, low-burden behavioral target that may be more attainable than structured exercise during active treatment. Continuous, objective monitoring of activity and symptoms using a wearable device, combined with tailored feedback, offers a practical approach for this population.

Objective: To develop a Capability, Opportunity, Motivation-Behavior (COM-B) based intervention to reduce sedentary behavior and promote physical activity in patients with colorectal cancer undergoing chemotherapy, and to evaluate its feasibility.

Intervention development: The intervention is developed using the COM-B model and the Behavior Change Wheel (BCW). A behavioral diagnosis is conducted across the COM-B components (capability, opportunity, motivation). Relevant intervention functions (education, training, enablement, environmental restructuring) and behavior change techniques (e.g., prompts/cues, self-monitoring of behavior, feedback on behavior, goal setting, problem solving, action planning, information about health consequences, verbal persuasion about capability, social rewards) are selected and mapped to interrupt prolonged sitting. The draft intervention undergoes expert review, and content validity is assessed using a 4-point scale with reference to the Item-level Content Validity Index (I-CVI) and Scale-level Content Validity Index (S-CVI); the intervention is refined based on expert feedback.

Study design and procedure: A single-group, non-randomized feasibility study with a pre-post test design is conducted. After providing written informed consent and confirming eligibility, each participant receives a study-provided smartwatch and participates in a 3-week intervention. Sedentary behavior and physical activity are recorded objectively by the smartwatch continuously for 3 weeks before, during, and 3 weeks after the intervention. The intervention comprises five core components, with the central target of interrupting prolonged sitting: when 60 minutes of continuous sitting is detected during waking hours, the participant is prompted to perform at least 1-2 minutes of light-intensity activity. The components are: (1) smartwatch-based sedentary prompts (vibration alerts after 60 minutes of continuous sitting, with guided light-activity options); (2) self-monitoring of sedentary behavior and physical activity via the smartwatch app; (3) structured weekly nurse feedback delivered by telephone (10-15 minutes; reviewing weekly activity data, reinforcing successes, and setting condition-adjusted goals); (4) weekly electronic symptom monitoring using the ESAS-r Cancer; and (5) tailored symptom-management education addressing treatment-related symptoms (e.g., fatigue, pain) as key barriers to reducing sedentary behavior. Survey-based outcomes are assessed at two time points (pre- and post-intervention) to enable pre-post comparison, scheduled to coincide with routine outpatient visits, so no additional hospital visits are required.

Measurements: Objective sedentary behavior and physical activity (smartwatch); subjective physical activity (GPAQ); symptoms and quality of life (EORTC QLQ-C30 \& CR29); self-efficacy to reduce sedentary behavior (SRSB); and feasibility of the intervention (acceptability, demand, implementation, practicality).

Sample size: Forty participants are enrolled. Statistical analysis: Data are analyzed using SPSS/WIN 29.0 (alpha = .05). General and clinical characteristics and all feasibility outcomes are summarized using descriptive statistics. As exploratory secondary analyses, changes in objective sedentary behavior and physical activity across the three time points (pre-, during, and post-intervention) are analyzed using repeated-measures ANOVA, and survey-based outcomes measured at two time points are compared using ANCOVA.

02

Conditions studied

  • Colorectal Neoplasms
  • Sedentary Behavior

Keywords

  • Colorectal cancer
  • Chemotherapy
  • Sedentary behavior
  • Physical activity
  • Wearable device
  • Behavior change
  • Feasibility study
03

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosed with colorectal cancer (stage 2 or 3) and scheduled to receive or currently receiving chemotherapy
  2. Able to use a smartwatch and respond to smartphone-based surveys
  3. Able to read and understand Korean and provide written informed consent
  4. ECOG performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  1. Newly advised by the attending physician to restrict physical activity
  2. Any injury or condition that, in the investigator's judgment, makes study participation inappropriate
04

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Intervention group

    All participants receive the 3-week smartwatch-based behavioral intervention to reduce sedentary behavior and promote physical activity. Sedentary behavior and physical activity are monitored using the smartwatch for 3 weeks before, throughout, and for 3 weeks after the intervention.

    Behavioral: Sedentary behavior reduction intervention for patients with colorectal cancer undergoing chemotherapy

Interventions

  • BehavioralSedentary behavior reduction intervention for patients with colorectal cancer undergoing chemotherapy

    A 3-week, COM-B based behavioral intervention delivered via a smartwatch, primarily targeting the interruption of prolonged sitting: when 60 minutes of continuous sitting is detected during waking hours, the participant is prompted to perform at least 1-2 minutes of light-intensity activity. It comprises five core components: (1) smartwatch-based sedentary prompts (vibration alerts after 60 minutes of continuous sitting, with guided light-activity options); (2) self-monitoring of sedentary behavior and physical activity; (3) structured weekly nurse feedback by telephone (10-15 minutes; reviewing weekly activity data, reinforcing successes, and setting condition-adjusted goals); (4) weekly electronic symptom monitoring using the ESAS-r Cancer; and (5) tailored symptom-management education addressing treatment-related symptoms (e.g., fatigue, pain) as key barriers to reducing sedentary behavior.

05

What researchers measure

Primary outcomes

  1. Feasibility of the intervention: acceptability

    Acceptability: satisfaction/ease/burden/recommendation, 5-point Likert

    Time frame: At 3 weeks after intervention start (immediately following completion of the intervention)

  2. Feasibility of the intervention: demand (1) Recruitment rate

    enrolled participants / eligible individuals approached (%)

    Time frame: At enrollment (baseline)

  3. Feasibility of the intervention: demand (2) Retention rate

    participants completing the post-intervention assessment / enrolled participants (%)

    Time frame: At 3 weeks after intervention start (immediately following completion of the intervention)

  4. Feasibility of the intervention: implementation (intervention adherence rate)

    overall adherence rate to intervention components (%)

    Time frame: At 3 weeks after intervention start (immediately following completion of the intervention)

  5. Feasibility of the intervention: practicality

    CTCAE-graded adverse events and technical faults (n)

    Time frame: At 3 weeks after intervention start (immediately following completion of the intervention)

Secondary outcomes

  1. Change from baseline in sedentary behavior

    Sedentary time (min/day)

    Time frame: Three weeks before, throughout the 3-week intervention, and three weeks after the intervention.

  2. Change from baseline in physical activity

    Physical activity time (min/day)

    Time frame: Three weeks before, throughout the 3-week intervention, and three weeks after the intervention.

  3. Change from baseline in symptoms at 3 weeks

    EORTC QLQ-C30/CR29 symptom scales (0-100; higher scores indicate worse symptoms)

    Time frame: Baseline and 3 weeks after intervention start

  4. Change from baseline in quality of life at 3 weeks

    EORTC QLQ-C30 global health status/QoL scale (0-100; higher scores indicate better quality of life)

    Time frame: Baseline and 3 weeks after intervention start

  5. Change from baseline in self-efficacy to reduce sedentary behavior at 3 weeks

    Self-Efficacy to Reduce Sedentary Behavior (SRSB) Questionnaire (9-item mean score, 1-5; higher scores indicate greater self-efficacy)

    Time frame: Baseline and 3 weeks after intervention start

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07845877
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Sep 29, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Jiyeon Lee, Professor
Contact
Jiyeonest@yuhs.ac
+82-2-2228-3255

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion